MEC1 and TEL1 encode ATR-and ATM-related proteins in the budding yeast Saccharomyces cerevisiae, respectively. Phleomycin is an agent that catalyzes double-strand breaks in DNA. We show here that both Mec1 and Tel1 regulate the checkpoint response following phleomycin treatment. MEC1 is required for Rad53 phosphorylation and cell-cycle progression delay following phleomycin treatment in G1, S or G2/M phases. The tel1D mutation confers a defect in the checkpoint responses to phleomycin treatment in S phase. In addition, the tel1D mutation enhances the mec1 defect in activation of the phleomycin-induced checkpoint pathway in S phase. In contrast, the tel1D mutation confers only a minor defect in the checkpoint responses in G1 phase and no apparent defect in G2/M phase. Methyl methanesulfonate (MMS) treatment also activates checkpoints, inducing Rad53 phosphorylation in S phase. MMS-induced Rad53 phosphorylation is not detected in mec1D mutants during S phase, but occurs in tel1D mutants similar to wild-type cells. Finally, Xrs2 is phosphorylated after phleomycin treatment in a TEL1-dependent manner during S phase, whereas no signi®cant Xrs2 phosphorylation is detected after MMS treatment. Together, our results support a model in which Tel1 contributes to checkpoint control in response to phleomycin-induced DNA damage in S phase.
INTRODUCTION
The genomes of eukaryotic cells are under continuous assault from extracellular genotoxic agents and the byproducts of intracellular processes including DNA replication. The resulting genetic damage may cause cell death or genetic instability that can lead to cancer. To ensure the proper response to genetic damage, cells have employed a set of surveillance mechanisms termed checkpoint controls (1, 2) .
Checkpoint pathways are an evolutionarily conserved feature of eukaryotic cells. This conservation is exempli®ed by the family of genes encoding high molecular weight protein kinases: ATM (mammals), ATR (mammals), MEC1 (Saccharomyces cerevisiae), TEL1 (S.cerevisiae), rad3 + (Schizosaccharomyces pombe) (2, 3) . Each of these gene products falls into two family groups based on homology; ATM is homologous to Tel1, while ATR is more related to Mec1 and Rad3. This homology is not restricted to the kinase domain at the C-terminus, but rather extends over the length of the protein. The C-terminal kinase domain is structurally related to the catalytic domain of the PI-3 kinases. Despite this similarity, none of these proteins has been shown to phosphorylate lipids. Instead, all these proteins are capable of phosphorylating protein substrates (4±8).
In the budding yeast S.cerevisiae, MEC1 plays a critical role in checkpoint control (1, 9) , whereas TEL1 shares an overlapping role with MEC1 in maintaining survival after DNA damage (10, 11) . Mec1 physically interacts with Lcd1 (also called Ddc2 and Pie1), a protein that exhibits limited homology to the S.pombe Rad26 and mammalian ATRIP proteins (8,12±15) . DNA damage responses have been well characterized in budding yeast, and consists of the G1-, S-and G2/M-phase damage checkpoints (9) . Mec1 and Lcd1 function as a complex that is essential for all three DNA damage checkpoints as well as the DNA replication block checkpoint. Similar to Mec1, Rad53 plays an essential role in both the DNA damage and replication block checkpoints (1, 9) . RAD53 encodes a protein kinase and functions not only downstream of MEC1 but also downstream of TEL1 (11, 16) . Following DNA damage and replication block, the Rad53 protein is hyperphosphorylated and activated by a mechanism dependent on Mec1. Consistent with their upstream role, both Mec1 and Lcd1 are recruited to sites of DNA damage, suggesting that the Mec1±Lcd1 complex interacts with aberrant DNA structures or the DNA repair apparatus after DNA damage (17±19). Thus, the Mec1±Lcd1 complex appears to recognize DNA damage and stalled DNA replication, and transduces a checkpoint signal to Rad53. *To whom correspondence should be addressed. Tel: +81 52 789 2593; Fax: +81 52 789 2589; Email: j46036a@nucc.cc.nagoya-u.ac.jp Present address: Toshiyasu Shimomura, Tsukuba Research Institute, Banyu Pharmaceutical Co., Ltd, Tsukuba 300-2611, Japan Additional DNA damage checkpoint genes in budding yeast are DDC1, MEC3, RAD9, RAD17 and RAD24. Rad9 is hyperphosphorylated following DNA damage in a MEC1-and TEL1-dependent manner, and the phosphorylated Rad9 protein binds to Rad53 and modulates its kinase activity (20, 21) . Genetic evidence has suggested that RAD17, RAD24, MEC3 and DDC1 operate in a common checkpoint pathway. Indeed, Ddc1, Mec3 and Rad17 interact physically with each other and function in a complex to control the DNA damage checkpoints (22) . It has been proposed that Ddc1, Mec3 and Rad17 are structurally related to PCNA (23) . RAD24 encodes a protein structurally related to the subunits of replication factor C which consists of the one large subunit Rfc1 and the four small subunits Rfc2, Rfc3, Rfc4 and Rfc5 (24, 25) . Rad24 regulates the recruitment of the Ddc1±Mec3±Rad17 complex to sites of DNA damage (17, 18) .
In mammals, the ATM gene has an established role in controlling the cellular responses to double-strand breaks (DSBs) (3). ATM is mutated in patients with the genetic disorder ataxia-telangiectasia (AT), and mice carrying mutations in ATM exhibit phenotypes similar to those of AT patients. AT cells exhibit chromosomal instability and defects in the cellular response to ionizing radiation at the G1, S and G2 phases. Ionizing radiation causes various types of DNA damage, among which DSBs are the most lethal. In addition, AT cells are sensitive to the anticancer drug bleomycin, which causes DSBs (26, 27) . To activate the checkpoint response, ATM collaborates with the Mre11±Rad50±Nbs11 complex which has been implicated in cellular responses to DSBs. Cells defective in the Nbs1 and Mre11 function shows phenotypes similar to AT cells (28) . Moreover, ATM phosphorylates Nbs1 to activate the S-phase checkpoint response (29±32). Thus, ATM and the Mre11±Rad50±Nbs1 complex appear to constitute a DNA damage response pathway. In budding yeast, the Mre11±Rad50±Xrs2 complex, which is related to the mammalian Mre11±Rad50±Nbs1 complex, plays an essential role in DSB processing (33) . Several lines of evidence have suggested that Tel1 and the Mre11±Rad50±Xrs2 complex also constitute a DNA damage response pathway. Cells carrying mre11D, rad50D or xrs2D mutations are sensitive to DNA damage, and are defective in checkpoint responses speci®cally to DSBs (34) . Although the tel1D mutation alone does not confer sensitivity to DNA damage, it does enhance sensitivity of mec1 mutants (10, 11) . Interestingly, mre11D and xrs2D mutations exacerbate the sensitivity of mec1 mutants to similar extents as a tel1D mutation (35, 36) . Furthermore, Mre11 and Xrs2 are phosphorylated after DNA damage in a TEL1-dependent manner (35, 36) . However, whether tel1D mutations confer a defect in checkpoint responses remains to be fully addressed.
The observation that ATM is speci®cally required for cellular responses to DSBs raises a possibility that Tel1 might have a similar role in the checkpoint responses following treatment with DSB-inducing agents. Phleomycin, like bleomycin, creates DSBs in DNA, but causes more signi®cant DNA lesions than bleomycin in budding yeast (37, 38) . In this study, we investigated whether TEL1 is involved in the checkpoint responses to phleomycin-induced DNA damage. We show that tel1D mutants are defective in delaying cellcycle progression after phleomycin treatment in S phase. Correspondingly, TEL1 is required for the phleomycininduced Rad53 phosphorylation in S phase. In contrast, MEC1 is required for the checkpoint responses to phleomycin treatment in G1, S and G2/M phases. Consistent with the previous ®nding that tel1D mutants are not defective in the S-phase regulation following methyl methanesulfonate (MMS) treatment, Rad53 is normally phosphorylated in tel1D mutants after MMS treatment during S phase. Phleomycin treatment induces Xrs2 phosphorylation in a TEL1-dependent manner during S phase, whereas MMS treatment does not cause signi®cant Xrs2 phosphorylation. These studies provide evidence that both Mec1 and Tel1 control the checkpoint responses to phleomycin-induced DNA damage.
MATERIALS AND METHODS

Strains, media and general methods
Yeast strains used in this study are isogenic and listed in Table 1 . The mec1-81 mutation was isolated by a synthetic lethal screen with a rnr1 mutation (T.Shimomura and K.Sugimoto, manuscript in preparation). Standard genetic techniques were used for manipulating yeast strains. Synthetic complete medium containing 0.5% casamino acids and the appropriate supplements was used to maintain selection of URA3 or TRP1 plasmids. All the culture was grown at 30°C.
Plasmids and strains construction
To construct the N-terminal HA-tagged TEL1, the 5¢-noncoding and N-terminal region of TEL1 gene were ampli®ed by polymerase chain reaction (PCR) with the 5¢-noncoding HA-TEL1 primers KS152: 5¢-TACGCGTAATC-TAC-3¢ and KS007: 5¢-TAATACGACTCACTATAGGG-CGA-3¢ or the N-terminal HA-TEL1 primers KS153: 5¢-TACGCGTATCCTTATGACGTACCAGATTATGCGGAG- (40), generating YCpT-XRS2-HA. The tagged XRS2 construct expressed appropriatesized proteins from its own promoter and complemented the xrs2 null mutation with respect to sensitivity to DNA damage. YCp-RAD53-HA, pGST-Rad53C, YEp-MEC1-HA and YEp-MEC1-KN-HA were described previously (8) . The tel1D::KanMX strain was constructed using pFA6a-kanMX4 as described (41) .
Drug sensitivity
To determine colony formation ability in the presence of phleomycin, cell cultures were serially diluted, spotted on YEPD plates with or without 5 mg/ml phleomycin (Sigma). To determine cell viability in high concentrations of phleomycin, yeast cells were incubated with 50 mg/ml phleomycin. At timed intervals, cells were withdrawn and spread on YEPD medium. After incubation for 3 days, the number of colonies was counted.
Immunoblotting analysis
Protein extracts for immunoblotting were prepared and resolved by electrophoresis on SDS±polyacrylamide gels as previously described (8) . To examine phosphorylation of Rad53 and Xrs2 in S phase, cells carrying YCp-RAD53-HA and YCpT-XRS2-HA, respectively, were arrested with 6 mg/ml a-factor for 120 min to synchronize cells in G1.
Cells were then washed to remove a-factor and released into fresh YEPD or YEPD containing 25 mg/ml phleomycin or 0.1% MMS. To examine Rad53 phosphorylation in G1 or G2/M phase, cells carrying YCp-RAD53-HA were arrested with 6 mg/ml a-factor or 15 mg/ml nocodazole for 120 min in G1 or G2/M, respectively. Cells were then treated with or without 50 mg/ml phleomycin maintaining the cell-cycle arrest.
Phleomycin-synchrony experiment
To examine regulation of the S phase, log-phase cultures were arrested with 6 mg/ml a-factor for 120 min to synchronize cells in G1 (25) . Cells were then washed to remove a-factor and released into fresh YEPD or YEPD containing 25 mg/ml phleomycin. To examine regulation of the G1-phase progression, cells were similarly arrested at G1 and incubated with 50 mg/ml phleomycin for 60 min. Cells were then washed to remove a-factor and phleomycin and released into fresh YEPD. Cells were withdrawn at different times and subjected to DNA¯ow cytometry analysis (42) . To analyze the cellcycle delay in G2/M, log-phase cultures were arrested with 15 mg/ml nocodazole for 120 min to synchronize cells in G2/M. Cells were treated with 50 mg/ml phleomycin for 60 min after arrest, and then washed to remove nocodazole and phleomycin and released into fresh YEPD. At timed intervals, cells were withdrawn and stained with 4¢,6-diamidino-2-phenylindole (DAPI) for microscopic examination (8) .
Immunoprecipitation and kinase assay
Immunoprecipitation was performed as described previously (8) . For the kinase assay, immunoprecipitates were separated into equal portions for immunoblotting and kinase reaction. Kinase assay was initiated in 40 ml of kinase buffer by the addition of 10 mCi [g-32 P]ATP (3000 Ci/mmol, Amersham Pharmacia Biotech), substrate (2 mg of GST-Rad53C and 0.6 mg of PHAS-1) and ATP to 100 mM. Reactions were terminated by addition of 5Q sample buffer and boiling for 5 min. The eluted proteins were separated by SDS±PAGE and gels were dried and autoradiographed.
RESULTS
Phleomycin-induced Rad53 phosphorylation dependent on MEC1 and TEL1
We investigated how Mec1 and Tel1 control cellular responses to treatment with the DSB-inducing agent phleomycin. Rad53 is modi®ed by phosphorylation in response to DNA damage or replication block, and its phosphorylation correlates with activation of the checkpoint pathways (11, 16) . We ®rst monitored Rad53 phosphorylation after phleomycin treatment in wild-type, mec1D and tel1D mutant cells. Because sml1 mutations suppress the lethality of mec1D but not the checkpoints (43) , all the genetic experiments were performed hereafter in an sml1D background. Cells expressing HAtagged Rad53 were incubated with 5 or 50 mg/ml phleomycin for 120 min, and Rad53 modi®cation was examined by immunoblotting analysis (Fig. 1) . After exposure to phleomycin, Rad53 modi®cation was detected in wild-type and tel1D cells in a dosage-dependent manner. In mec1D cells, Rad53 modi®cation was observed after treatment with Nucleic Acids Research, 2003, Vol. 31, No. 6 1717 expression level of HA-tagged Rad53 was not altered in wildtype, mec1D or tel1D mutant cells (data not shown). These results suggest that mec1D mutants retain a residual activity to phosphorylate Rad53 in response to phleomycin treatment, and that TEL1 might be involved in activation of the checkpoint pathways after phleomycin treatment.
Requirement of MEC1 and TEL1 for checkpoint response after phleomycin treatment in S phase
In budding yeast, DNA damage activates the checkpoint pathways in G1, S and G2/M phases. We ®rst investigated the roles of Mec1 and Tel1 in the S-phase checkpoint response to phleomycin treatment. The S-phase checkpoint was analyzed by monitoring the DNA content of phleomycin-treated cells after release from the G1 block ( Fig. 2A) . When released from a-factor arrest and treated with 25 mg/ml phleomycin, the S-phase progression was delayed in wild-type cells as evidenced by lower rates of DNA synthesis. Compared with wild-type cells, mec1D mutants were slow in the S-phase progression in the absence of phleomycin, suggesting that the mec1D defect is not completely suppressed by the sml1D mutation. Phleomycin treatment further delayed the S-phase progression of mec1D mutants (see the cytometry pro®les at 40 min after release). However, mec1D cells progressed through S phase faster than wild-type cells in the presence of phleomycin. Similarly, tel1D mutants delayed the S-phase progression, but progressed through S phase faster than wildtype cells in the presence of phleomycin. These results show that both mec1D and tel1D mutants are partially defective in the S-phase checkpoint after phleomycin treatment.
We next compared induction of Rad53 phosphorylation by phleomycin treatment in wild-type, mec1D and tel1D cells. Cells expressing Rad53-HA were synchronized by a-factor and released into medium containing 25 mg/ml phleomycin (Fig. 2B) . We found that Rad53 became phosphorylated within 30 min in wild-type cells. However, in mec1D mutants, no Rad53 phosphorylation was detected at 30 min after release. Although Rad53 phosphorylation became apparent in mec1D mutants at the later time points, its phosphorylation was clearly decreased as evidenced by the appearance of more weakly smeared bands in mec1D cells than wild-type cells. In tel1D cells, Rad53 phosphorylation was not detected at 30 min after release, but became apparent at 50 min after release at levels much greater than in mec1D cells. The phosphorylation observed in tel1D cells may result from the progression of cells into G2/M phase, because tel1D cells are pro®cient in Rad53 phosphorylation in response to phleomycin treatment in G2/M phase whereas mec1D cells are not (see below). These results indicate that both MEC1 and TEL1 are required for the S-phase checkpoint following phleomycin treatment.
We further investigated the additive effect of the mec1 and tel1 mutations on the cell-cycle progression. For this purpose, we used a weak mec1 (mec1-81) allele in combination with the tel1D mutation, because the mec1D tel1D double mutation confers a senescent phenotype resulting in a growth defect (7, 44) . In contrast to mec1D tel1D double mutants, mec1-81 tel1D double mutants grow as well as wild-type cells (see Fig. 7 ). We found that mec1-81 single and mec1-81 tel1D double mutants were defective in the S-phase checkpoint; these mutants progressed faster than wild-type cells in the presence of phleomycin (Fig. 2A) . However, it was dif®cult to determine the additive defect in the cell-cycle delay. Similar to mec1D mutants, these mec1-81 mutants were slow in the S-phase progression in the absence of phleomycin, whereas tel1D mutants were not. We then examined Rad53 phosphorylation in mec1-81 and mec1-81 tel1D double mutants. While residual Rad53 phosphorylation was observed in both mec1-81 and tel1D cells, no phosphorylation was detectable in mec1-81 tel1D double mutants. Together, these results indicate that Mec1 and Tel1 act in parallel to activate the S-phase checkpoint responses following phleomycin treatment.
Involvement of MEC1 and TEL1 in the G1 damage checkpoint induced by phleomycin treatment
We next investigated the G1-phase checkpoint of mec1 and tel1 mutants cells after phleomycin treatment. We ®rst examined the delay in cell-cycle progression at the G1-to S-phase transition after DNA damage by monitoring cellular DNA content (Fig. 3A) . Phleomycin treatment induced a G1-phase arrest in wild-type cells and the arrest continued for 120 min. Although mec1D cells exhibited delayed progression into S phase, these cells apparently progressed from G1 phase much faster than wild-type cells. We found that tel1D mutants were a little defective in delaying progression into S phase. We also examined the cell-cycle progression in mec1-81 and mec1-81 tel1D double mutants, and found that these mutants were defective in the G1 checkpoint. However, it was not determined whether the introduction of the tel1D mutation enhances the defect of the mec1-81 mutation. As discussed above, mec1-81 and mec1-81 tel1D mutants were slow in cellcycle progression through S phase in the absence of phleomycin, whereas tel1D mutants were not.
We then monitored phleomycin-induced Rad53 phosphorylation in G1-arrested cells (Fig. 3B) . Rad53 phosphorylation became visible in the G1-arrested mec1D cells, but its phosphorylation was signi®cantly decreased compared with the wild-type cells. Although Rad53 phosphorylation was detectable in tel1D mutants as in wild-type cells at 120 min after phleomycin treatment, it was clearly decreased in tel1D mutants at 60 min after treatment. We also examined the Rad53 phosphorylation in mec1-81 and mec1-81 tel1D double mutants. Similar to mec1D cells, the phleomycin-induced Rad53 phosphorylation was detectable, but was signi®cantly decreased in mec1-81 mutants arrested in G1. No phosphorylation was observed in the G1-arrested mec1-81 tel1D double mutants. Thus, as observed for the S-phase checkpoint, Mec1 and Tel1 affect Rad53 modi®cation and cell-cycle delay in a Figure 1 . Effect of the mec1D and tel1D mutations on phleomycin-induced Rad53 phosphorylation. Wild-type (KSC1178), mec1D (KSC1186) and tel1D (KSC1368) cells carrying YCp-RAD53-HA were untreated or treated with 5 or 50 mg/ml phleomycin for 120 min. Cell extracts were then subjected to immunoblotting analysis with anti-HA antibodies as described in Materials and Methods.
parallel manner in G1 phase, but the role of Tel1 in delaying cell-cycle progression seems not to be pronounced in G1 phase.
Effect of the mec1 and tel1 mutations on the G2/M checkpoint following phleomycin treatment
We further investigated the G2/M-phase DNA damage checkpoint in mec1 and tel1 mutant cells after phleomycin treatment. We examined the cell-cycle arrest of mec1D and tel1D cells following DNA damage by monitoring mitotic division (Fig. 4A) . When cell cultures were released from nocodazole arrest after phleomycin treatment, wild-type cells showed delayed nuclear division, whereas mec1D proceeded through mitosis faster than wild-type cells. In contrast to mec1D mutants, tel1D mutants underwent mitosis at the same rate as wild-type cells. We also monitored Rad53 phosphorylation status in mec1D and tel1D mutant cells arrested with nocodazole in G2/M (Fig. 4B) . Upon exposure to phleomycin, Rad53 became highly phosphorylated in tel1D mutants as well as wild-type cells. In contrast, no apparent phosphorylation was detected in mec1D mutants. These results indicate that MEC1 is essential for the G2/M-phase response to phleomycin-induced DNA damage, whereas TEL1 contributes little to this checkpoint.
Effect of the mec1D and tel1D mutations on checkpoint responses after MMS treatment in S phase
The above results indicate that Mec1 and Tel1 are both required for the S-phase checkpoint response after phleomycin treatment. However, it has been demonstrated that mec1D mutants are defective in the S-phase checkpoint induced by MMS treatment, whereas tel1D mutants are not (45, 46) . MMS is an alkylating agent and generates methylated purines (N 3 -methyladenine, N 7 -methylguanine and O 6 -methylguanine) in DNA (47) . Thus, MMS produces primary DNA lesions that are different from those produced by phleomycin, although MMS could create DSBs secondarily at high concentrations. To further assess the function of Mec1 and Tel1 in the MMSinduced S-phase checkpoint response, we monitored Rad53 phosphorylation in mec1D and tel1D mutant cells (Fig. 5 ). Cells were arrested with a-factor, and then released from afactor into medium containing 0.1% MMS. To monitor Rad53 phosphorylation, we here used a higher concentration of MMS than previously used (45, 46) . Under these conditions, all the cells remained in S phase for 60 min after release from the G1 arrest (Fig. 5) . However, consistent with the previous ®ndings (45, 46) , mec1D mutants underwent S-phase progression a little faster than wild-type and tel1D mutant cells. MMS treatment induced Rad53 phosphorylation in tel1D mutants as observed Figure 2 . Checkpoint responses after phleomycin treatment in S phase. (A) The S-phase checkpoint response to phleomycin. Cells were synchronized with a-factor in G1 and released in either the presence or the absence of 25 mg/ml phleomycin (PM). Aliquots of cells were collected at the indicated times after release from a-factor treatment and subjected to¯ow cytometric analyses as described in Materials and Methods. Dotted lines indicate the DNA content of 1C and 2C cells. The top panels represent asynchronous (As) cells not treated with phleomycin and are included as a reference. (B) Kinetics of Rad53 phosphorylation after release from G1 arrest into phleomycin. Cells carrying YCp-RAD53-HA were arrested in G1 with a-factor and released in medium containing 25 mg/ml phleomycin as in (A). Cells were harvested at time indicated and subjected to immunoblotting analysis. Strains used are wild-type (KSC1178), mec1D (KSC1186), tel1D (KSC1368), mec1-81 (KSC1400) and mec1-81 tel1D (KSC1402).
in wild-type cells. In contrast, no apparent phosphorylation was detectable in mec1D cells after the same MMS treatment. Thus, Mec1 and Tel1 respond differently to DNA damage induced by phleomycin and MMS in S phase.
Xrs2 phosphorylation in mec1D and tel1D mutants after treatment with phleomycin or MMS during S phase Mre11, Rad50 and Xrs2 form a complex which is required for DSB repair in budding yeast (33) . The Mre11±Rad50±Xrs2 complex appears to be targeted by Tel1 after DNA damage (35, 36) . Mre11 and Xrs2 are phosphorylated after DNA damage in a TEL1-dependent manner, and their phosphorylation is detectable as slowly migrating forms by immunoblotting analysis (35, 36) . Because Tel1 is required for the S-phase checkpoint response after phleomycin treatment but not MMS treatment, we examined the phosphorylation status of Xrs2 during S phase in mec1D and tel1D mutants. Cells expressing HA-tagged Xrs2 were arrested with a-factor, and then released from a-factor into medium containing 25 mg/ml phleomycin or 0.1% MMS as described above (see Figs 2 and 5) . Xrs2 phosphorylation was observed after phleomycin treatment in wild-type cells, whereas no signi®cant phosphorylation was detected after MMS treatment (Fig. 6) . The phleomycin-induced Xrs2 phosphorylation was largely dependent on Tel1, because its phosphorylation was abolished by the introduction of the tel1D mutation but not the mec1D mutation (Fig. 6) . These results are consistent with the model in which Tel1 is required for the S-phase checkpoint response after phleomycin treatment.
Effect of the tel1D mutation on cell viability after phleomycin treatment
Because both mec1 and tel1 mutants are defective in phleomycin-induced checkpoints, we examined whether the mec1 and tel1 mutations confer sensitivity to phleomycin. Cells carrying mec1D and mec1-81 mutations were hypersensitive to phleomycin, whereas tel1D mutants were no more sensitive than wild-type cells (Fig. 7) . The tel1D mutation had no effect on cell viability after short exposure to high concentrations of phleomycin (data not shown). However, introduction of the tel1D mutation enhanced sensitivity to phleomycin in mec1-81 mutant cells (Fig. 7) . These results indicate that MEC1 has an essential role in phleomycininduced DNA damage repair and that TEL1 has an overlapping role with MEC1.
In vitro phosphorylation by Mec1 and Tel1
Mec1 and Tel1 play a redundant role in activation of the checkpoint pathway, but Mec1 plays a more signi®cant role than Tel1. One explanation could be that Mec1 and Tel1 have Figure 3 . Checkpoint responses after phleomycin treatment in G1 phase. (A) Cell-cycle progression at the G1/S transition after phleomycin treatment. Cells were synchronized with a-factor in G1 and further treated with 50 mg/ml phleomycin for 60 min, and then released from a-factor and phleomycin into YEPD as described in Materials and Methods. Aliquots of cells were collected at the indicated times after release from a-factor treatment and examined for DNA content by¯ow cytometry. (B) Rad53 phosphorylation after phleomycin treatment in G1 phase. Cells carrying YCp-RAD53-HA were arrested in G1 with a-factor and untreated or treated with 50 mg/ml phleomycin for 60 or 120 min maintaining the G1 arrest and then subjected to immunoblotting analysis. Strains used are wild-type (KSC1178), mec1D (KSC1186), tel1D (KSC1368), mec1-81 (KSC1400), mec1-81 tel1D (KSC1402). different substrate preference. It has been shown that both Mec1 and Tel1 phosphorylate PHAS-1 in vitro (7), and that Mec1 phosphorylates the C-terminal half of Rad53 in vitro (8). We ®rst asked whether Tel1 phosphorylates the C-terminal half of Rad53 in vitro as Mec1 does. For this purpose, we generated an HA-tagged TEL1 construct (TEL1-HA). Tel1 contains the motif DXXXXN at positions 2612±2616, which plays a critical role in protein kinase catalysis. We mutated this conserved motif to AXXXXS and constructed a kinasenegative version of TEL1-HA (tel1-KN-HA). Rad53 has 16 SQ/TQ motifs; eight of them are located in the N-terminus including the kinase domain, and eight are in the C-terminus. To examine Rad53 phosphorylation, GST fusion proteins with the C-terminal half of Rad53 (GST-Rad53C) were expressed and puri®ed from bacteria (8) . PHAS-1 also contains SQ/TQ motifs (7). Extracts were prepared from cells expressing Tel1-HA, Tel1-KN-HA or no HA-tagged protein, and were immunoprecipitated with anti-HA antibodies. Immunoprecipitates were then subjected to an in vitro kinase assay. GST-Rad53C and PHAS-1 were phosphorylated by the immunoprecipitates containing Tel1-HA but not by the immunoprecipitates containing Tel1-KN-HA or no HAtagged protein (Fig. 8A) . No speci®c phosphorylation of GST alone was observed with Tel1-HA (data not shown). Consistent with the previous ®ndings (7, 8) , Mec1 phosphorylated GST-Rad53C and PHAS-1 (Fig. 8A) . Our analysis, however, does not exclude the possibility that Mec1 and Tel1 phosphorylate others than SQ/TQ motifs in GST-Rad53C and PHAS-1.
We then performed the Mec1 and Tel1 kinase assay in the presence of the same amounts of PHAS-1 and GSTRad53C substrates. In these reactions, Mec1 phosphorylated GST-Rad53C more ef®ciently than Tel1 did, whereas Tel1 phosphorylated PHAS-1 more ef®ciently than Mec1 did (Fig. 8B) . Both Tel1 and Mec1 were fused to the same HA tag at their N-termini (see Materials and Methods) and the amounts of each protein in the immunoprecipitates were estimated to be similar by immunoblotting analysis (Fig. 8B) . Together, these results suggest that Mec1 and Tel1 have different substrate preferences in vitro.
DISCUSSION
In mammalian cells, both ATM and ATR have been implicated in the response to DSB-inducing ionizing radiation. Both ATR-related and ATM-related proteins are also found in budding yeast, encoded by MEC1 and TEL1, respectively. Genetic and biochemical studies have demonstrated that Mec1 plays a central role in the DNA damage checkpoint, but the function of Tel1 in checkpoints has not been well characterized. Since ATM is speci®cally required for checkpoint responses to DSBs, we hypothesized that Tel1 might have a similar role. In this report, we investigated the roles of Mec1 and Tel1 in the checkpoint responses to phleomycin, an agent that causes DSBs in DNA. Phleomycin, like other DNA-damaging agents, induces Rad53 phosphorylation in cells. MEC1 is required for Rad53 phosphorylation and cellcycle arrest following phleomycin treatment in all the G1, S and G2/M phases. In contrast, TEL1 is required for Rad53 phosphorylation and cell-cycle arrest in S phase. TEL1 is as well partially required for Rad53 phosphorylation and cell-cycle arrest in G1 phase, but not in G2/M phase. Consistent with the role of Tel1 in the S-phase regulation, Xrs2 is phosphorylated after phleomycin treatment in a Similar to phleomycin treatment, MMS treatment activates checkpoints and induces Rad53 phosphorylation in S phase. However, mec1 and tel1 mutants behave differently in response to MMS treatment; mec1 mutants are defective in the S-phase checkpoint after MMS treatment whereas tel1D Figure 5 . Effect of the mec1D and tel1D mutations on the MMS-induced Rad53 phosphorylation in S phase. Wild-type (KSC1178), mec1D (KSC1186) and tel1D (KSC1368) cells carrying YCp-RAD53-HA were synchronized with a-factor in G1 and released in 0.1% MMS as in Figure 2 . Aliquots of cells were collected at the indicated times after release from a-factor treatment and subjected to immunoblotting (A) and¯ow cytometric analyses (B) as in Figure 2 . Figure 6 . Effect of the mec1D and tel1D mutations on Xrs2 phosphorylation after phleomycin and MMS treatment in S phase. Wild-type (KSC1178), mec1D (KSC1186) and tel1D (KSC1368) cells carrying YCpT-XRS2-HA were synchronized with a-factor in G1 and released into 25 mg/ml phleomycin or 0.1% MMS as in Figure 2 . Aliquots of cells were collected at the indicated times after release from a-factor treatment and subjected to immunoblotting. Figure 7 . Effect of the mec1 and tel1 mutations on sensitivity to phleomycin. Wild-type (KSC1178), mec1D (KSC1186), tel1D (KSC1368), mec1-81 (KSC1400), mec1-81 tel1D (KSC1402) cells were grown to log phase and cell cultures were serially diluted, spotted on the YEPD plates with or without 5 mg/ml phleomycin. . Cells were grown to the mid-log phase and harvested for preparation of crude extracts. Extracts were subjected to immunoprecipitation with anti-HA antibodies. The immunoprecipitated HA-tagged Mec1 and Tel1 proteins were assayed for kinase activity using GST-Rad53C or PHAS-1 as a substrate as described in Materials and Methods. In each of the top three panels, 32 P incorporation into GST-Rad53C or PHAS-1 was detected by autoradiography. In each of the bottom panels, the amount of the Mec1 or Tel1 protein used for the kinase assay was examined by immunoblotting with anti-HA antibodies. (B) Substrate preference of Mec1 and Tel1. Extracts were prepared from MEC1-HA (KSC1212), TEL1-HA (KSC1517) and untagged (KSC006) cells. The kinase assay was performed with GST-Rad53C (2 mg) and PHAS-1 (0.6 mg), and 32 P incorporation was detected by autoradiography. In the bottom panel, the amount of the Mec1 and Tel1 protein used for the kinase assay was examined by immunoblotting. The star indicates bands which were detectable without addition of substrate (data not shown). mutants are not (45, 46) . Correspondingly, MMS treatment induces Rad53 phosphorylation in tel1D mutants as observed in wild-type cells, but the phosphorylation is not detected in mec1D mutants. Together, these results support a model in which Mec1 and Tel1 regulate pathways in parallel and are activated by different types of DNA damage.
Cells carrying the tel1D mutation are defective in delaying cell-cycle progression in S phase when DNA is damaged by phleomycin. In contrast, tel1D mutants are only weakly defective in the G1-phase responses and pro®cient in the G2/M-phase responses following phleomycin treatment. Thus, the checkpoint defect in tel1D mutants upon the occurrence of DSBs appears to be mainly caused by the inability to cope with DSBs in S phase. One possible explanation was that the checkpoint defect observed in tel1D mutants could be attributed, at least in part, to the cell-cycle-dependent expression of Mec1 and/or Tel1. However, the expression levels of both Mec1 and Tel1 are not altered during the cell cycle (data not shown). Alternatively, DSBs might be more improperly processed during S phase than G1 or G2/M phase, resulting in activation of a TEL1-dependent checkpoint response. Consistent with this possibility, Usui et al. (36) have demonstrated that sae2 and rad50s mutations, which cause a defect in DSB processing, enhance the Tel1-mediated checkpoint response.
Rad53 is phosphorylated in response to DNA damage, and its phosphorylation is correlated with activation of the Rad53 kinase. We showed that phleomycin treatment induces Rad53 phosphorylation in a MEC1-and TEL1-dependent manner. Recent evidence has suggested that Rad53 phosphorylation following DNA damage might result entirely from increased autophosphorylation activity (20) . However, DNA damage induces hyperphosphorylation of Rad53 mutant proteins which possess little autophosphorylation activity (48) . Thus, after DNA damage Rad53 becomes phosphorylated in trans in a Mec1-and Tel1-dependent manner. Consistently, both Mec1 and Tel1 were found to phosphorylate the Rad53 protein in vitro.
It has been suggested that DNA damage accumulates more in checkpoint defective mutants than wild-type cells. Although tel1D mutants are defective in the S-phase checkpoint, they do not show hypersensitivity to phleomycin. One explanation could be that a functional G2/M checkpoint compensates for defects in S phase. Perhaps if the G2/M checkpoint is fully functional and activated, DNA damage might be repaired suf®ciently to allow cells to remain viable. Indeed, similar phenotypes have been observed in several mec1 mutants (49); these mutants are as defective as mec1D in both the G1-and S-phase checkpoints following treatment with UV light and MMS, although they do not show hypersensitivity to UV or MMS. Alternatively, it is possible that in tel1D mutants DNA damage accumulates but might be processed ef®ciently by the MEC1-dependent repair pathway. Supporting this, the tel1D mutation was found to enhance sensitivity of mec1 mutants to phleomycin.
The human genes mutated in AT and Nijmegen breakage syndrome, ATM and NBS1, respectively, are both involved in the cellular response to DSBs (2,3). The Nbs1 protein forms a complex with the human Mre11 and Rad50 proteins, which are implicated in DSB repair (50) . Mutations in the MRE11 gene were also found in individuals with another AT-like disorder (51) . Moreover, ATM directly phosphorylates Nbs1 on several sites required for its checkpoint function in vivo (30±32). These results have demonstrated a functional and biochemical link between ATM and the Mre11±Rad50±Nbs1 complex in human cells. The budding yeast Mre11± Rad50±Xrs2 complex has an established role in both nonhomologous end-joining and homologous recombination repair of DSBs (33) . Recently, several groups showed that the Mre11±Rad50±Xrs2 complex is required for checkpoint responses after treatment of DSB-inducing agents (34±36). It has been also shown that mre11D and xrs2D mutations enhance the DNA-damage sensitivity of mec1 mutants to similar extents as a tel1D mutation (35, 36) . Moreover, Mre11 and Xrs2 are phosphorylated after DNA damage in a TEL1-dependent manner (35, 36) . These ®ndings have suggested the model in which Tel1 and the Mre11±Rad50±Xrs2 complex constitute a DNA damage response pathway (35, 36) . We have shown that Tel1 is required for Xrs2 phosphorylation as well as checkpoint responses after phleomycin treatment in S phase. Our results extend the notion that the Mre11±Rad50±Nbs1/Xrs2 complex and ATM family protein are structurally and functionally conserved in eukaryotes.
